Autologous mesenchymal stem cell-based cellular therapy impacts peripheral blood immunocompetent cells’ content in patients with symptomatic epilepsy

Kosmacheva S.M., Goncharova N.V., Potapnev M.P., Moroz L.A., Hlebokazov F.P., Dakukina N.V.

Republican Scientific and Practical Center for Transfusiology&Medical BioTechnologies, Minsk, Belarus
Republican Scientific and Practical Center for Mental Health, Minsk, Belarus

Peripheral blood lymphocyte subsets in patients with symptomatic epilepsy (SE) were evaluated by flow cytomentry before (n=32) and after (n=12) first course of cellular therapy using autologous mesenchymal stem cells (autoMSCs). ItwasshownthatpatientsrevealedhighercontentofCD3+CD16+CD56+ NKT cells and TcRγδ+cells as well as lower content of CD3+CD4+ T cells when compared to healthy control subjects. After 6-7 days post starting of cellular therapy with autoMSCs in peripheral blood of patients with SE we detected increased up to normal content of CD3+CD4+ T cells,and decreased level of CD3+HLA-DR+ activated T cells, CD3+CD8+CD57+ cytotoxic T cells, CD3+CD8+CD45RA naïve T cells. We concluded that MSCs-based cellular therapy of patients with SE possessed direct immunomodulation upon impaired T cell subsets’ content in peripheral blood prior to beneficial clinical effect.